Jardine Matheson Holdings Limited · SGX:J36
Jardine Matheson — I-MED Radiology Network — Investor Day (June 2026)
19 slides from Jardine Matheson's investor day presentation, June 2026
Slide 1: Introduction to I-MED Radiology Network
Introduction to I-MED Radiology Network June 2026
Slide 2: Dr Shrey Viranna and Clare Battellino
DR SHREY VIRANNA DR SHREY VIRANNA Chief Executive Officer Chief Executive Officer & Executive Director & Executive Director Dr Shrey Viranna Clare Battellino Chief Executive Officer & Executive Chief Financial Officer & Executive Director Director • CEO since March 2020; previously • CFO since Augus
Slide 3: I-MED – the leader in ANZ diagnostic imaging and a global teleradiology platform
Introduction I-MED – the leader in ANZ diagnostic imaging and a global teleradiology platform Largest ANZ provider and one of the largest globally I-MED geographic footprint4 One of the world’s largest diagnostic Hospital Clinics imaging platforms 3.3m patients and 8.8m scans per annum1 Freestanding
Slide 4: I-MED's aim is to be the most respected and trusted medical imaging specialist in the world
Introduction I-MED’s aim is to be the most respected and trusted medical imaging specialist in the world I-MED’s purpose is to save lives and reduce uncertainty Working Together Innovation Compassion Connection Quality With our referrers, Through finding new and Treat our patients, Built on one netw
Slide 5: Outstanding long-term track record of resilient growth set to continue
Introduction Outstanding long-term track record of resilient growth set to continue Leveraging Benefits of Scale & Expansion & Resilient Technology Differentiation Brand Unification & Service through COVID 2024+ Technology Investments 2020-2023 Platform Build 2018-2020 • Teleradiology expansion into
Slide 6: I-MED's scale, technology and integration delivers strong clinical, operational and commercial outcomes
Introduction I-MED’s scale, technology and integration delivers strong clinical, operational and commercial outcomes Integration Scale Outcomes Unified operating model across the full Largest network of clinics, doctors and network of clinics patients in ANZ Unified tech stack, integrated acro
Slide 7: Why I-MED?
Why I-MED? Why I-MED? 1 Highly defensive sector with strong long-term tailwinds 2 Scale, market leadership and clinical excellence creates I-MED’s competitive advantage 3 Unified platform delivers material strategic advantages 4 I-MED is at the forefront of technology & AI-enabled workflow 5 Market
Slide 8: Highly stable long-term Australian market growth, which has accelerated since FY22
Why I-MED? Highly defensive sector with strong long-term tailwinds 1 Highly stable long-term Australian market growth, which has accelerated since FY22 Australian DI growth has been consistent and strong over decades Growth has accelerated and outlook remains highly predictable Australian Medicare-f
Slide 9: I-MED is the largest scale player in ANZ by a wide margin
Why I-MED? Scale, market leadership and clinical excellence creates I-MED’s competitive advantage 2 I-MED is the largest scale player in ANZ by a wide margin Largest diagnostic imaging provider in ANZ Largest diagnostic imaging geographic footprint in ANZ I-MED ANZ clinic network overview FY25 Reven
Slide 10: I-MED's clinical excellence drives strong engagement with radiologists and referrers
Why I-MED? Scale, market leadership and clinical excellence creates I-MED’s competitive advantage 2 I-MED’s clinical excellence drives strong engagement with radiologists and referrers Clinical excellence is core to I-MED’s success… …reinforcing I-MED’s reputation amongst radiologists… Number of rad
Slide 11: I-MED has a market leading position in high value hospital locations in Australia
Why I-MED? Scale, market leadership and clinical excellence creates I-MED’s competitive advantage 2 I-MED has a market leading position in high value hospital locations in Australia I-MED’s scale and capabilities drive an outsized share of hospital …providing a reliable revenue stream and privileged
Slide 12: Market-leading integrated technology and AI underpin every aspect of I-MED's business
Why I-MED? I-MED is at the forefront of technology and AI-enabled workflow 4 Market-leading integrated technology and AI underpin every aspect of I-MED’s business Referral and booking Scan Interpretation Reporting Results and review End-to-end operations Pricing National Workload Sharing Diagnostic
Slide 13: I-MED has built a leading global teleradiology platform with outstanding growth
Why I-MED? Market leadership in teleradiology delivers significant incremental growth & TAM 5 I-MED has built a leading global teleradiology platform with outstanding growth I-MED’s Teleradiology business has delivered strong revenue With a dominant position in ANZ, and strategic expansion into the
Slide 14: I-MED has significant growth levers in its core business and markets
Why I-MED? Material further growth levers, with strong execution & ROI track record 6 I-MED has significant growth levers in its core business and markets 3 2 1 EBITDA A$256m 1 EBITDA FY25 Growth opportunities Future 1 2 3 ANZ network growth & optimisation Targeted ANZ network expansion Global teler
Slide 15: I-MED has a strong pipeline of opportunities to grow its network
Why I-MED? Material further growth levers, with strong execution & ROI track record I-MED has a strong pipeline of opportunities to grow its network, with a repeatable model 6 to generate attractive ROIs Significant whitespace opportunity despite strong existing market share Strong pipeline of organ
Slide 16: In the longer term, there are opportunities to leverage I-MED's scale and leadership
Why I-MED? Material further growth levers, with strong execution & ROI track record 6 In the longer term, there are opportunities to leverage I-MED’s scale and leadership Broad playing field of viable expansion plays… … with three particularly compelling growth vectors Data and 1 ANZ diagnostics Tec
Slide 17: I-MED has demonstrated strong growth and financial performance
Why I-MED? Material further growth levers, with strong execution & ROI track record 6 I-MED has demonstrated strong growth and financial performance Revenue (A$m) EBITDA (A$m)1 EBITDA 16.5% 16.7% 17.6% 18.1% margin (%) 1,576 285 1,451 256 1,269 1,181 212 195 2 2 FY23 FY24 FY25 FY26PF FY23 FY24 FY25
Slide 18: World class senior management team with deep organisational talent and proven governance model
Why I-MED? World-class management & governance model World class senior management team with deep organisational talent and proven 7 governance model World-Class Senior Executive Senior executive team with world- class DI / healthcare experience and track record DR SHREY VIRANNA CLARE BATTELLINO D
Slide 19: Legal disclaimer
Legal disclaimer This document has been prepared by Image Holdco Pty Ltd (ACN 623 028 740) (Company) for information purposes only The Relevant Information includes views and judgements expressed by employees of the Company. These views and to facilitate interested parties’ understanding of the Comp